Biogen Inc
NASDAQ:BIIB

Watchlist Manager
Biogen Inc Logo
Biogen Inc
NASDAQ:BIIB
Watchlist
Price: 148.43 USD 1.34%
Market Cap: 21.6B USD
Have any thoughts about
Biogen Inc?
Write Note

Biogen Inc
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biogen Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Biogen Inc
NASDAQ:BIIB
Free Cash Flow
$1.8B
CAGR 3-Years
-6%
CAGR 5-Years
-23%
CAGR 10-Years
-4%
Abbvie Inc
NYSE:ABBV
Free Cash Flow
$15.6B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Free Cash Flow
$10B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Free Cash Flow
$6.3B
CAGR 3-Years
-7%
CAGR 5-Years
-7%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Free Cash Flow
-$1.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Free Cash Flow
$3.3B
CAGR 3-Years
-15%
CAGR 5-Years
11%
CAGR 10-Years
20%
No Stocks Found

Biogen Inc
Glance View

Market Cap
21.5B USD
Industry
Biotechnology
Economic Moat
None

Biogen Inc. finds its roots in the cutting-edge world of biotechnology, where science meets the needs of patients battling complex neurological diseases. Founded in 1978 by a group of visionary scientists, including Nobel laureates, Biogen has evolved into a leader known primarily for its focus on neuroscience. Nestled in Cambridge, Massachusetts, the company operates with a singular goal—transforming the understanding and treatment of neurological disorders. The enterprise drives its mission through rigorous research and development (R&D), which forms the backbone of its operations. Biogen invests substantial resources in unveiling the mysteries of diseases such as multiple sclerosis (MS), Alzheimer's, and spinal muscular atrophy, striving to pioneer therapies that can profoundly improve patient outcomes. Biogen's revenue model is heavily contingent upon the successful commercialization of its R&D endeavors. The company primarily earns its revenue by developing and marketing prescription drugs that target neurological conditions. Signature products, such as Tecfidera, Tysabri, and Spinraza, have become mainstays in the management of multiple sclerosis and spinal muscular atrophy, respectively, delivering significant returns. By continually reinvesting in its drug pipeline, Biogen stays at the forefront of biopharmaceutical innovation, seeking to expand its portfolio and rigging favorable licensing deals and collaborations along the way. These elements ensure not just the sustenance but also the growth of its market presence, driving the company forward in a competitive and ever-evolving industry landscape.

BIIB Intrinsic Value
208.22 USD
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Biogen Inc's Free Cash Flow?
Free Cash Flow
1.8B USD

Based on the financial report for Sep 30, 2024, Biogen Inc's Free Cash Flow amounts to 1.8B USD.

What is Biogen Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-4%

Over the last year, the Free Cash Flow growth was 72%. The average annual Free Cash Flow growth rates for Biogen Inc have been -6% over the past three years , -23% over the past five years , and -4% over the past ten years .

Back to Top